Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III
NCT ID: NCT00846274
Last Updated: 2009-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2008-10-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation
NCT01886248
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
NCT06594146
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
NCT03275740
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
NCT03097341
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antithrombin III
SK Antithrombin III
SK Antithrombin III
SK Antithrombin III
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SK Antithrombin III
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight: More than 50kg
* Healthy male subject
Exclusion Criteria
* ATIII hypersensitivity
19 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Anam Hospital
OTHER
SK Chemicals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SK Chemicals Co.,Ltd.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ji Young Park, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Anam Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SK chemicals
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim KA, Lim YY, Kim SH, Park JY. Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects. Clin Ther. 2013 Nov;35(11):1752-61. doi: 10.1016/j.clinthera.2013.08.018. Epub 2013 Oct 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKATIII_I_2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.